Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Je, H. | - |
dc.contributor.author | Nam, G.-H. | - |
dc.contributor.author | Kim, G.B. | - |
dc.contributor.author | Kim, W. | - |
dc.contributor.author | Kim, S.R. | - |
dc.contributor.author | Kim, I.-S. | - |
dc.contributor.author | Lee, E.J. | - |
dc.date.accessioned | 2021-12-03T08:41:27Z | - |
dc.date.available | 2021-12-03T08:41:27Z | - |
dc.date.created | 2021-08-31 | - |
dc.date.issued | 2021-03-10 | - |
dc.identifier.issn | 0168-3659 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/129079 | - |
dc.description.abstract | Tumor-specific apoptosis-inducing ligands have attracted considerable attention in cancer therapy. But, the evasion of apoptosis by tumors can cause acquired resistance to the therapy. TNF-related apoptosis-inducing ligand (TRAIL) has been investigated as an ideal antitumor agent owing to its inherent tumor cell-specific apoptotic activity. However, there are several barriers to its wider application, including the inability for stable formation of the trimeric structure, poor stability and pharmacokinetics, and differences in the sensitivity of different tumor types. Especially, almost 70% of tumor cells have acquired resistance to TRAIL, leading to failure of TRAIL-based therapeutics in clinical trials. To overcome therapeutic efficiency limitations against TRAIL-resistant tumors, we exploited the characteristic of a naturally derived nanocage that not only delivers TRAIL in its native-like trimeric structure, but also delivers a drug (doxorubicin [DOX]) that re-sensitizes TRAIL-resistant tumor cells. These TRAIL-presenting nanocages (TTPNs) showed high loading efficiency, pH-dependent release profiles, and effective intracellular delivery of the re-sensitizing agent DOX. As a result, DOX-TTPNs efficiently re-sensitized TRAIL-resistant tumor cells to TRAIL-mediated apoptosis in vitro by regulating levels of the TRAIL receptor, DR5, and anti- and pro-apoptotic proteins involved in extrinsic and intrinsic apoptosis pathways. We further demonstrated the antitumor efficacy of DOX-TTPNs in vivo, showing that even at a very low dose, the incorporated DOX successfully re-sensitized tumors to the apoptotic effects of TRAIL, underscoring the potential of this platform as an antitumor agent. Given that other homotrimeric TNF superfamily ligands and immunotherapeutic agents can be substituted for TRAIL ligand and re-sensitizing drugs on the surface and in the inner cavity of the nanocage, respectively, this platform is potentially suitable for development of a broad range of anticancer or immunotherapeutic combinations. © 2021 Elsevier B.V. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Elsevier B.V. | - |
dc.subject | Cell death | - |
dc.subject | Controlled drug delivery | - |
dc.subject | Efficiency | - |
dc.subject | Ligands | - |
dc.subject | Organic polymers | - |
dc.subject | Targeted drug delivery | - |
dc.subject | Acquired resistance | - |
dc.subject | Anti-tumor efficacy | - |
dc.subject | Apoptosis pathways | - |
dc.subject | Apoptotic activity | - |
dc.subject | Intracellular delivery | - |
dc.subject | Ph-dependent release | - |
dc.subject | Therapeutic efficiency | - |
dc.subject | Trimeric structure | - |
dc.subject | Tumors | - |
dc.subject | buffer | - |
dc.subject | caspase 3 | - |
dc.subject | caspase 8 | - |
dc.subject | death receptor 5 | - |
dc.subject | doxorubicin | - |
dc.subject | monomer | - |
dc.subject | nanocage | - |
dc.subject | nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase | - |
dc.subject | protein bcl xl | - |
dc.subject | tumor necrosis factor related apoptosis inducing ligand | - |
dc.subject | tumor necrosis factor related apoptosis inducing ligand receptor | - |
dc.subject | X linked inhibitor of apoptosis | - |
dc.subject | animal experiment | - |
dc.subject | animal model | - |
dc.subject | apoptosis | - |
dc.subject | Article | - |
dc.subject | cell death | - |
dc.subject | cell membrane | - |
dc.subject | cell viability | - |
dc.subject | comparative study | - |
dc.subject | controlled study | - |
dc.subject | elution | - |
dc.subject | endocytosis | - |
dc.subject | fluorescence intensity | - |
dc.subject | fluorescence microscopy | - |
dc.subject | Hep-G2 cell line | - |
dc.subject | HT-29 cell line | - |
dc.subject | human | - |
dc.subject | human cell | - |
dc.subject | in vitro study | - |
dc.subject | internalization (cell) | - |
dc.subject | lysosome | - |
dc.subject | MCF-7 cell line | - |
dc.subject | mouse | - |
dc.subject | nonhuman | - |
dc.subject | pH | - |
dc.subject | photon correlation spectroscopy | - |
dc.subject | physical chemistry | - |
dc.subject | polyacrylamide gel electrophoresis | - |
dc.subject | priority journal | - |
dc.subject | size exclusion chromatography | - |
dc.subject | transmission electron microscopy | - |
dc.subject | tumor volume | - |
dc.subject | TUNEL assay | - |
dc.title | Overcoming therapeutic efficiency limitations against TRAIL-resistant tumors using re-sensitizing agent-loaded trimeric TRAIL-presenting nanocages | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, I.-S. | - |
dc.identifier.doi | 10.1016/j.jconrel.2021.01.016 | - |
dc.identifier.scopusid | 2-s2.0-85100151080 | - |
dc.identifier.wosid | 000626476700002 | - |
dc.identifier.bibliographicCitation | Journal of Controlled Release, v.331, pp.7 - 18 | - |
dc.relation.isPartOf | Journal of Controlled Release | - |
dc.citation.title | Journal of Controlled Release | - |
dc.citation.volume | 331 | - |
dc.citation.startPage | 7 | - |
dc.citation.endPage | 18 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | Cell death | - |
dc.subject.keywordPlus | Controlled drug delivery | - |
dc.subject.keywordPlus | Efficiency | - |
dc.subject.keywordPlus | Ligands | - |
dc.subject.keywordPlus | Organic polymers | - |
dc.subject.keywordPlus | Targeted drug delivery | - |
dc.subject.keywordPlus | Acquired resistance | - |
dc.subject.keywordPlus | Anti-tumor efficacy | - |
dc.subject.keywordPlus | Apoptosis pathways | - |
dc.subject.keywordPlus | Apoptotic activity | - |
dc.subject.keywordPlus | Intracellular delivery | - |
dc.subject.keywordPlus | Ph-dependent release | - |
dc.subject.keywordPlus | Therapeutic efficiency | - |
dc.subject.keywordPlus | Trimeric structure | - |
dc.subject.keywordPlus | Tumors | - |
dc.subject.keywordPlus | buffer | - |
dc.subject.keywordPlus | caspase 3 | - |
dc.subject.keywordPlus | caspase 8 | - |
dc.subject.keywordPlus | death receptor 5 | - |
dc.subject.keywordPlus | doxorubicin | - |
dc.subject.keywordPlus | monomer | - |
dc.subject.keywordPlus | nanocage | - |
dc.subject.keywordPlus | nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase | - |
dc.subject.keywordPlus | protein bcl xl | - |
dc.subject.keywordPlus | tumor necrosis factor related apoptosis inducing ligand | - |
dc.subject.keywordPlus | tumor necrosis factor related apoptosis inducing ligand receptor | - |
dc.subject.keywordPlus | X linked inhibitor of apoptosis | - |
dc.subject.keywordPlus | animal experiment | - |
dc.subject.keywordPlus | animal model | - |
dc.subject.keywordPlus | apoptosis | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | cell death | - |
dc.subject.keywordPlus | cell membrane | - |
dc.subject.keywordPlus | cell viability | - |
dc.subject.keywordPlus | comparative study | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | elution | - |
dc.subject.keywordPlus | endocytosis | - |
dc.subject.keywordPlus | fluorescence intensity | - |
dc.subject.keywordPlus | fluorescence microscopy | - |
dc.subject.keywordPlus | Hep-G2 cell line | - |
dc.subject.keywordPlus | HT-29 cell line | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human cell | - |
dc.subject.keywordPlus | in vitro study | - |
dc.subject.keywordPlus | internalization (cell) | - |
dc.subject.keywordPlus | lysosome | - |
dc.subject.keywordPlus | MCF-7 cell line | - |
dc.subject.keywordPlus | mouse | - |
dc.subject.keywordPlus | nonhuman | - |
dc.subject.keywordPlus | pH | - |
dc.subject.keywordPlus | photon correlation spectroscopy | - |
dc.subject.keywordPlus | physical chemistry | - |
dc.subject.keywordPlus | polyacrylamide gel electrophoresis | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | size exclusion chromatography | - |
dc.subject.keywordPlus | transmission electron microscopy | - |
dc.subject.keywordPlus | tumor volume | - |
dc.subject.keywordPlus | TUNEL assay | - |
dc.subject.keywordAuthor | Protein Nanocage | - |
dc.subject.keywordAuthor | Re-sensitization | - |
dc.subject.keywordAuthor | Resistance | - |
dc.subject.keywordAuthor | Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) | - |
dc.subject.keywordAuthor | Tumor-specific apoptosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.